TABLE 3.
Comparison of biomarkers for subgroups of MGMT status.
| Patients with LGG (WHO II and III) | |||
| Parameter | MGMT + (mean ± SD) | MGMT – (mean ± SD) | FDR-adjusted p-value |
| OEF (%) | 18.99 ± 5.65 | 20.70 ± 5.68 | 0.408† |
| Ktrans (mL/min) | 0.03 ± 0.01 | 0.06 ± 0.05 | 0.080‡ |
| CBV (mL/100 g) | 1.96 ± 1.05 | 3.27 ± 2.50 | 0.200‡ |
| CBF (mL/100 g per min) | 161.37 ± 75.27 | 217.20 ± 130.81 | 0.225‡ |
|
| |||
|
Patients with GBM (WHO IV)
| |||
| Parameter | MGMT+(mean ± SD) | MGMT – (mean ± SD) | FDR-adjusted p-value |
|
| |||
| OEF (%) | 20.19 ± 4.74 | 25.17 ± 5.35 | 0.01 ‡ |
| Ktrans (mL/min) | 0.09 ± 0.07 | 0.10 ± 0.05 | 0.397‡ |
| CBV (mL/100 g) | 4.17 ± 2.37 | 5.09 ± 3.04 | 0.420‡ |
| CBF (mL/100 g per min) | 308.45 ± 213.63 | 312.88 ± 136.05 | 0.585‡ |
OEF, oxygen extraction fraction; Ktrans, volume transfer constant, CBV, cerebral blood volume, CBF, cerebral blood flow.
p-values were calculated using Student t-test† or Wilcoxon rank-sum test‡ with false discovery rate (FDR) correction (<0.05). Statistically significant p-values are highlighted in bold.